Phase 4 N=26 Examining the Role of Improved NSAID Management in Treating Dysmenorrhea and Bladder Pain
Dysmenorrhea · Pain
Primary: Change in Menstrual Pain — 4.1 score on a scale — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=83 Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects
Post-surgical Ocular Inflammation · Post-surgical Ocular Pain
Primary: Anterior Chamber Cell (ACC) Grade: Number of Participants Achieving an ACC Grade of 0 — 22; 9 Participants — p=<0.001
Phase 3 N=360 APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Primary: Change From Baseline at Month 12 in Six-Minute Walk Test (6-MWT) — -21.345; -8.150 meters — p=0.0162
Phase 2 N=3 A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages
Paranasal Sinus Cancer · Nasal Cavity Tumor · Nasal Cavity Adenocarcinoma
Primary: Local Control Assessment of Unresectable Paranasal Sinus and Nasal Cavity Tumors
N/A N=49 DEMA-Pro Intervention for Seniors With Subjective Cognitive Decline and Living at Home
Subjective Cognitive Decline
Primary: Physical Function — -4.7 score on a scale
Phase 3 N=74 Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery
Non-obstructive Azoospermia
Primary: Pain Score as Measured by the NRS-11 Scale — 1.91; 3.05; 2.27; 3.24 scores on a scale — p=0.01
N/A N=121 A Clinical Study for Validating the Equivalence of Bloomlife MFM-Pro to Clinical Standard-of-care for Performing Antepartum Fetal Monitoring
Fetal Monitoring
Primary: Extent of Agreement Between Bloomlife MFM-Pro and CTG in Fetal Heart Rate — -5.46; -5.57; 6.04; 6.04 BPM
Phase 2 N=11 Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI
Pulmonary Vascular Disease
Primary: Percent Change in Abnormal RBC Percentage — -17.7 percent change
N/A N=102 A Prospective Study of Human Bone Adaptation Using a Novel in Vivo Loading Model
Bone Loss
Primary: Change in UD iBMC — 0.0049; -0.0020; 0.0252; 0.0309 g — p=0.119
Phase 4 N=28 Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis
Multiple Sclerosis
Primary: Overactive Bladder Symptom Composite Score (OAB-SCS) at Baseline vs. Final Visit — 3.01; 2.56 score on a scale
Phase 2 N=176 ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
Age-related Macular Degeneration
Primary: LL BCVA Score Change From Baseline — 0.7; -0.6; 1.1; -0.8 Letters
Phase 4 N=41 Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
Dermatitis Atopic
Primary: Percent Change From Baseline in Transepidermal Water Loss (TEWL) After 5 Skin Tape Stripping (STS) on Lesional Skin (LS) in AD Participants at Week 16 — -38.5633 percent…
Phase 4 N=45 Bilateral Continuous Erector Spinae Blocks for Post-Sternotomy Pain Management
Postoperative Pain
Primary: Analgesic Requirement — 0.60 (mg/kg)
Phase 3 N=5 Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A
Molybdenum Cofactor Deficiency, Type A
Primary: Overall Survival — 3 Participants
Phase 2 N=46 Nicotinamide as an Early Alzheimer's Disease Treatment
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Change in P-tau 231 — 4.71; 2.28 pg/ml — p=0.6096